Newson Rachel S, Barraclough Helen, Lapthorn Jennifer, Stewart Martin, Colman Sam, D'Emden Michael
Medical Affairs, Eli Lilly and Company, Sydney, NSW, Australia.
Real-World Evidence, Fortrea, Sydney, NSW, Australia.
Patient Prefer Adherence. 2025 Apr 4;19:897-905. doi: 10.2147/PPA.S503673. eCollection 2025.
As more treatments become available to normalize glycated hemoglobin (HbA1c) levels and reduce weight, it is important to understand the meaningfulness of achieving target HbA1c levels and weight reduction from the perspective of people with type 2 diabetes.
This is a cross-sectional survey of 300 Australians with type 2 diabetes.
Achieving target HbA1c levels was meaningful to 90.0% (n=198) and moderately/very/extremely important to 94.5% (n=208) of the 220 participants with HbA1c >6.0%. Over half of the participants were dissatisfied with their current weight (n=158, 52.7%) and underreported their body mass index category (n=160, 53.3%). For 59.0% (n=177), a mean (±standard deviation) of 17.2 (±20.6) kg of weight loss was meaningful. Of these participants, 10.7%, 30.5%, 21.5%, and 37.3% viewed 5%, 5-10%, 10%-15%, and >15% of weight reduction as meaningful, respectively.
According to this survey, achieving target HbA1c levels is both meaningful and important to most people with type 2 diabetes. Achieving weight reduction is also seen as important despite frequent underrating of body mass index. Therapies targeting both target HbA1c levels and weight reduction may be of interest to people with type 2 diabetes in Australia, and this could impact medication adherence and health outcomes.
随着越来越多的治疗方法可用于使糖化血红蛋白(HbA1c)水平正常化并减轻体重,从2型糖尿病患者的角度理解实现目标HbA1c水平和体重减轻的意义非常重要。
这是一项对300名澳大利亚2型糖尿病患者的横断面调查。
在220名HbA1c>6.0%的参与者中,90.0%(n=198)认为实现目标HbA1c水平有意义,94.5%(n=208)认为适度/非常/极其重要。超过一半的参与者对自己目前的体重不满意(n=158,52.7%),并且低估了自己的体重指数类别(n=160,53.3%)。对于59.0%(n=177)的参与者来说,平均(±标准差)减轻17.2(±20.6)kg体重是有意义的。在这些参与者中,分别有10.7%、30.5%、21.5%和37.3%认为减轻5%、5%-10%、10%-15%和>15%的体重是有意义的。
根据这项调查,实现目标HbA1c水平对大多数2型糖尿病患者来说既有意义又很重要。尽管体重指数经常被低估,但减轻体重也被视为很重要。针对目标HbA1c水平和体重减轻的治疗方法可能会引起澳大利亚2型糖尿病患者的兴趣,这可能会影响药物依从性和健康结果。